701 related articles for article (PubMed ID: 22310612)
1. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
Tsai SF; Cheng CY; Shu KH; Wu MJ
Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
[TBL] [Abstract][Full Text] [Related]
2. Trends in the use of immunosuppressive agents by outpatients after renal transplantation at a medical center in southern Taiwan.
Mao PC; Lee EK; Tseng PL
Transplant Proc; 2012 Jan; 44(1):185-9. PubMed ID: 22310611
[TBL] [Abstract][Full Text] [Related]
3. Trends in the use of maintenance immunosuppressive drugs among liver transplant recipients in Taiwan: a nationwide population-based study.
Huang YY; Hsu CC; Chou CL; Loong CC; Wu MS; Chou YC
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):661-7. PubMed ID: 26799240
[TBL] [Abstract][Full Text] [Related]
4. Prescription trends of immunosuppressive drugs in post-heart transplant recipients in Taiwan, 2000-2009.
Chou CL; Chou CY; Huang YY; Wu MS; Hsu CC; Chou YC
Pharmacoepidemiol Drug Saf; 2014 Dec; 23(12):1312-9. PubMed ID: 25335855
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
Pescovitz MD; Govani M
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S16-21. PubMed ID: 11583940
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
8. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
9. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
[TBL] [Abstract][Full Text] [Related]
10. Switching immunosuppression medications after renal transplantation--a common practice.
Meier-Kriesche HU; Chu AH; David KM; Chi-Burris K; Steffen BJ
Nephrol Dial Transplant; 2006 Aug; 21(8):2256-62. PubMed ID: 16574677
[TBL] [Abstract][Full Text] [Related]
11. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
12. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
13. Steroid-free maintenance immunosuppression with rapamune and low-dose neoral in pancreas transplant recipients.
Rajab A; Pelletier RP; Ferguson RM; Elkhammas EA; Bumgardner GL; Henry ML
Transplantation; 2007 Nov; 84(9):1131-7. PubMed ID: 17998868
[TBL] [Abstract][Full Text] [Related]
14. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
15. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
[TBL] [Abstract][Full Text] [Related]
16. [Immunosuppression for kidney transplant recipients: current strategies].
Alberú J; Urrea EM
Rev Invest Clin; 2005; 57(2):213-24. PubMed ID: 16524061
[TBL] [Abstract][Full Text] [Related]
17. Trends in immunosuppressive therapy: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).
Benfield MR; Stablein D; Tejani A
Pediatr Transplant; 1999 Feb; 3(1):27-32. PubMed ID: 10359028
[TBL] [Abstract][Full Text] [Related]
18. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
20. [Toward an evidence-based immunosuppression].
Pascual J
Nefrologia; 2001; 21(6):524-5; discussion 526-7. PubMed ID: 11881421
[No Abstract] [Full Text] [Related]
[Next] [New Search]
